"Hormone-replacement therapy (HRT) can improve not only bone-mineral density (BMD) but bone mass and structure, and the benefits of HRT on bone persist for at least 2 years after treatment is discontinued, a new cross-sectional analysis of a Swiss"...
Overdosage of estrogen may cause nausea, vomiting, breast tenderness, abdominal pain, drowsiness and fatigue, and withdrawal bleeding may occur in women. Treatment of overdose consists of discontinuation of MINIVELLE therapy with institution of appropriate symptomatic care.
MINIVELLE is contraindicated in women with any of the following conditions:
- Undiagnosed abnormal genital bleeding
- Known, suspected or history of breast cancer
- Known or suspected estrogen-dependent neoplasia
- Active DVT, PE, or a history of these conditions
- Active arterial thromboembolic disease (for example, stroke and MI), or a history of these conditions
- Known anaphylactic reaction or angioedema with MINIVELLE
- Known liver impairment
- Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders
- Known or suspected pregnancy
Last reviewed on RxList: 2/28/2017
Additional Minivelle Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.